>
Switch to:

Fate Therapeutics Shiller PE Ratio

: (As of Today)
View and export this data going back to 2013. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Fate Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Fate Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fate Therapeutics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Fate Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Fate Therapeutics Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Shiller PE Ratio falls into.



Fate Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Fate Therapeutics's E10 for the fiscal year that ended in Dec20 is calculated as:

For example, Fate Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec20 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec20 (Change)*Current CPI (Dec20)
=-2.1/109.8968*109.8968
=-2.100

Current CPI (Dec20) = 109.8968.

Fate Therapeutics Annual Data

Earnings per Share (Diluted) CPI Adj_EPS
201112 -1.514 95.213 -1.747
201212 -1.606 96.871 -1.822
201312 -3.540 98.326 -3.957
201412 -1.270 99.070 -1.409
201512 -1.180 99.792 -1.299
201612 -1.050 101.863 -1.133
201712 -1.020 104.011 -1.078
201812 -1.190 105.998 -1.234
201912 -1.440 108.420 -1.460
202012 -2.100 109.897 -2.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fate Therapeutics  (NAS:FATE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Fate Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fate Therapeutics Business Description

Fate Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2836
Traded in Other Exchanges
Address
3535 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
Tahl Cindy officer: General Counsel and Secretary C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, STE 200 SAN DIEGO CA 92121
Shoemaker Daniel D officer: Chief Scientific Officer C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121
Valamehr Bahram officer: Chief Development Officer C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, STE 200 SAN DIEGO CA 92121
Dulac Edward J Iii officer: Chief Financial Officer FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT STE 200 SAN DIEGO CA 92121
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Green Jeremy director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D SUITE D3-300 SAN FRANCISCO CA 94129
Jooss Karin director C/O GRITSTONE ONCOLOGY, INC. 5858 HORTON STREET, SUITE 210 EMERYVILLE CA 94608
Agarwal Shefali director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Mendlein John director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: MENDLEIN JOHN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Rastetter William H director 9885 TOWNE CENTRE DR. SAN DIEGO CA 92121
Hershberg Robert director 3005 FIRST AVENUE SEATTLE WA 98121
Coughlin Timothy director 339 NORTH GRANADOS AVE SOLANA BEACH CA 92075
Lee Michael Stewart director C/O REDMILE GROUP, LLC ONE LETTERMAN DR., BLDG. D, SUITE D3-300 SAN FRANCISCO CA 94129
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Wolchko J Scott director, officer: President and CEO C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121

Fate Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)